Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Publications (2 of 2) Show all publications
Karlsson, P. A., Pärssinen, J., Danielsson, E. A., Fatsis-Kavalopoulos, N., Frithiof, R., Hultström, M., . . . Wang, H. (2023). Antibiotic use during coronavirus disease 2019 intensive care unit shape multidrug resistance bacteriuria: A Swedish longitudinal prospective study. Frontiers in Medicine, 10, Article ID 1087446.
Open this publication in new window or tab >>Antibiotic use during coronavirus disease 2019 intensive care unit shape multidrug resistance bacteriuria: A Swedish longitudinal prospective study
Show others...
2023 (English)In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 10, article id 1087446Article in journal (Refereed) Published
Abstract [en]

Objectives: High frequency of antimicrobial prescription and the nature of prolonged illness in COVID-19 increases risk for complicated bacteriuria and antibiotic resistance. We investigated risk factors for bacteriuria in the ICU and the correlation between antibiotic treatment and persistent bacteria.

Methods: We conducted a prospective longitudinal study with urine from indwelling catheters of 101 ICU patients from Uppsala University Hospital, Sweden. Samples were screened and isolates confirmed with MALDI-TOF and whole genome sequencing. Isolates were analyzed for AMR using broth microdilution. Clinical data were assessed for correlation with bacteriuria.

Results: Length of stay linearly correlated with bacteriuria (R2 = 0.99, p ≤ 0.0001). 90% of patients received antibiotics, primarily the beta-lactams (76%) cefotaxime, piperacillin-tazobactam, and meropenem. We found high prevalence of Enterococcus (42%) being associated with increased cefotaxime prescription. Antibiotic-susceptible E. coli were found to cause bacteriuria despite concurrent antibiotic treatment when found in co-culture with Enterococcus.

Conclusion: Longer stays in ICUs increase the risk for bacteriuria in a predictable manner. Likely, high use of cefotaxime drives Enterococcus prevalence, which in turn permit co-colonizing Gram-negative bacteria. Our results suggest biofilms in urinary catheters as a reservoir of pathogenic bacteria with the potential to develop and disseminate AMR.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2023
Keywords
UTI, ICU–intensive care unit, COVID-19, MDR–(multidrug resistance), AMR, antibiotic treatment, catheters
National Category
Anesthesiology and Intensive Care Infectious Medicine Clinical Medicine Microbiology in the medical area Public Health, Global Health and Social Medicine
Research subject
Anaesthesiology and Intensive Care; Microbiology; Epidemiology; Urology; Pharmaceutical Microbiology; Clinical Bacteriology; Clinical Pharmacology
Identifiers
urn:nbn:se:uu:diva-496102 (URN)10.3389/fmed.2023.1087446 (DOI)000934136200001 ()36824610 (PubMedID)
Funder
Swedish Society for Medical Research (SSMF), S18-0174Swedish Research Council, 2018-02376Swedish Research Council, 2014-02569Swedish Research Council, 2014-07606Knut and Alice Wallenberg Foundation, 2020.0182Knut and Alice Wallenberg Foundation, 2020.0241Swedish Heart Lung Foundation, 20210089Swedish Heart Lung Foundation, 20190639Swedish Heart Lung Foundation, 20190637The Swedish Kidney Foundation, F2020-0054Science for Life Laboratory, SciLifeLab
Available from: 2023-02-07 Created: 2023-02-07 Last updated: 2026-02-02Bibliographically approved
Cardenas, E. I., Alvarado-Vazquez, P. A., Mendez-Enriquez, E., Danielsson, E. A. & Hallgren, J. (2022). Elastase- and LPS-Exposed Cpa3(Cre/+) and ST2(-/-) Mice Develop Unimpaired Obstructive Pulmonary Disease. Frontiers in Immunology, 13, Article ID 830859.
Open this publication in new window or tab >>Elastase- and LPS-Exposed Cpa3(Cre/+) and ST2(-/-) Mice Develop Unimpaired Obstructive Pulmonary Disease
Show others...
2022 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 13, article id 830859Article in journal (Refereed) Published
Abstract [en]

IL-33 and its receptor ST2, as well as mast cells and their mediators, have been implicated in the development of chronic obstructive pulmonary disease (COPD). However, whether mast cells and the ST2 receptor play a critical role in COPD pathophysiology remains unclear. Here, we performed repeated intranasal administrations of porcine pancreatic elastase and LPS for four weeks to study COPD-like disease in wildtype, ST2-deficient, and Cpa3(Cre/+) mice, which lack mast cells and have a partial reduction in basophils. Alveolar enlargement and changes in spirometry-like parameters, e.g. increased dynamic compliance and decreased expiratory capacity, were evident one day after the final LPS challenge and worsened over time. The elastase/LPS model also induced mild COPD-like airway inflammation, which encompassed a transient increase in lung mast cell progenitors, but not in mature mast cells. While ST2-deficient and Cpa3(Cre/+) mice developed reduced pulmonary function uninterruptedly, they had a defective inflammatory response. Importantly, both ST2-deficient and Cpa3(Cre/+) mice had fewer alveolar macrophages, known effector cells in COPD. Elastase/LPS instillation in vivo also caused increased bronchiole contraction in precision cut lung slices challenged with methacholine ex vivo, which occurred in a mast cell-independent fashion. Taken together, our data suggest that the ST2 receptor and mast cells play a minor role in COPD pathophysiology by sustaining alveolar macrophages.

Place, publisher, year, edition, pages
Frontiers Media S.A.Frontiers Media SA, 2022
Keywords
COPD, chronic obstructive pulmonary disease, pulmonary function, airway hyperresposiveness, mast cell (MC), ST2, IL-33
National Category
Respiratory Medicine and Allergy Immunology in the medical area
Identifiers
urn:nbn:se:uu:diva-474696 (URN)10.3389/fimmu.2022.830859 (DOI)000792759600001 ()35493481 (PubMedID)
Funder
Swedish Research CouncilSwedish Heart Lung FoundationKnut and Alice Wallenberg FoundationAgnes and Mac Rudberg FoundationMalin och Lennart Philipsons StiftelseStiftelsen Apotekare Hedbergs Fund for Medical ResearchStiftelsen G A Johanssons MinnesfondP.O. Zetterling Foundation
Available from: 2022-05-25 Created: 2022-05-25 Last updated: 2024-01-17Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-9146-7965

Search in DiVA

Show all publications